Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign up Log in
Powered By

Top 10 search results for "Clinical trials" in Resources. To see all results and access other features, sign up for free.

... References NIH Clinical Research Trials and You — National Institutes of Health ClinicalTrials.gov — National Library of Medicine Clinical Trials and Human Subject Protection — U.S. Food and Drug Administration Informed Consent FAQs — U.S. Department of Health and Human Services ...
Clinical Trials for HS: 6 Facts To Know
... References NIH Clinical Research Trials and You — National Institutes of Health ClinicalTrials.gov — National Library of Medicine Clinical Trials and Human Subject Protection — U.S. Food and Drug Administration Informed Consent FAQs — U.S. Department of Health and Human Services ...
... References Efficacy and Safety of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa (BE HEARD I and BE HEARD II): Two 48-Week, Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase 3 Trials — The Lancet FDA Approves Bimzelx for Adults With Moderate to Severe Hidradenitis Suppurativa — Healio UCB Receives U.S. ...
Newly Approved Drug Reduces HS Symptoms by 50% in Trials
... References Efficacy and Safety of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa (BE HEARD I and BE HEARD II): Two 48-Week, Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase 3 Trials — The Lancet FDA Approves Bimzelx for Adults With Moderate to Severe Hidradenitis Suppurativa — Healio UCB Receives U.S. ...
... References Povorcitinib Demonstrates Promising Phase 3 Results for Hidradenitis Suppurativa Treatment — Dermatology Times Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa — Business Wire ...
40% See HS Symptom Reduction in Povorcitinib Study
... References Povorcitinib Demonstrates Promising Phase 3 Results for Hidradenitis Suppurativa Treatment — Dermatology Times Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa — Business Wire ...
... Unlike the biologics currently approved for HS, povorcitinib is taken as a pill, not an injection.In a recent clinical trial, povorcitinib was shown to reduce the total number of HS abscesses and nodules by over half. ...
New HS Treatments: Latest FDA-Approved Options
... Unlike the biologics currently approved for HS, povorcitinib is taken as a pill, not an injection.In a recent clinical trial, povorcitinib was shown to reduce the total number of HS abscesses and nodules by over half. ...
... References Hidradenitis Suppurativa — Epidemiology, Clinical Presentation, and Pathogenesis — The Journal of the American Academy of Dermatology Hidradenitis Suppurativa — National Organization for Rare Disorders The Most Recent Advances in Understanding and Managing Hidradenitis Suppurativa — F1000 Research Anti-Inflammatory Effect of Curcuma Longa ...
Turmeric for Hidradenitis Suppurativa: Does It Help?
... References Hidradenitis Suppurativa — Epidemiology, Clinical Presentation, and Pathogenesis — The Journal of the American Academy of Dermatology Hidradenitis Suppurativa — National Organization for Rare Disorders The Most Recent Advances in Understanding and Managing Hidradenitis Suppurativa — F1000 Research Anti-Inflammatory Effect of Curcuma Longa ...
... StatPearls Sexual Dysfunction in Patients With Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis — Journal of Clinical and Aesthetic Dermatology Hidradenitis Suppurativa and Sleep: A Systematic Review — Archives of Dermatological Research Retrospective Cohort Study of Pregnancy Outcomes in Hidradenitis Suppurativa — Henry Ford Health ...
Hidradenitis Suppurativa Pain: Causes and Treatments
... StatPearls Sexual Dysfunction in Patients With Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis — Journal of Clinical and Aesthetic Dermatology Hidradenitis Suppurativa and Sleep: A Systematic Review — Archives of Dermatological Research Retrospective Cohort Study of Pregnancy Outcomes in Hidradenitis Suppurativa — Henry Ford Health ...
... References Health Information — Magnesium — National Institutes of Health Topical Medications and Washes — Hidradenitis Suppurativa Patient Guide Effect of Magnesium Supplementation on Inflammatory Parameters: A Meta-Analysis of Randomized Controlled Trials — Nutrients Should You Take an Epsom Salt Bath? ...
Magnesium for Hidradenitis Suppurativa: Can It Help?
... References Health Information — Magnesium — National Institutes of Health Topical Medications and Washes — Hidradenitis Suppurativa Patient Guide Effect of Magnesium Supplementation on Inflammatory Parameters: A Meta-Analysis of Randomized Controlled Trials — Nutrients Should You Take an Epsom Salt Bath? ...
... They can also keep you up to date on current clinical trials, case reports, and other news about your condition. Are There Overlapping Medications?Because of the symptom similarities between HS and spondylitis, some medications can be used to treat either condition (and often both). ...
Spondylitis and Hidradenitis Suppurativa: Is There a Connection?
... They can also keep you up to date on current clinical trials, case reports, and other news about your condition. Are There Overlapping Medications?Because of the symptom similarities between HS and spondylitis, some medications can be used to treat either condition (and often both). ...
... In clinical trials, more than 85 percent of people in the study maintained their treatment response over two years, and the amount of people with severe disease dropped from 87.4 percent to 20.4 percent​.Bimekizumab was approved by the U.S. Food and Drug Administration (FDA) in November 2024 for the treatment of moderate to severe HS in adults. ...
Bimekizumab Reduces Severe HS by 75% Over Two Years
... In clinical trials, more than 85 percent of people in the study maintained their treatment response over two years, and the amount of people with severe disease dropped from 87.4 percent to 20.4 percent​.Bimekizumab was approved by the U.S. Food and Drug Administration (FDA) in November 2024 for the treatment of moderate to severe HS in adults. ...
... Kim’s research on innate immunity and neuroimmune regulation of AD and itch has led to awards and funding from the National Institutes of Health, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, American Society for Clinical Investigation, American Dermatological Association, and the International League ...
Watch on Demand: Straight Talk on Skin Conditions With Dr. Kim and Dr. Richmond
... Kim’s research on innate immunity and neuroimmune regulation of AD and itch has led to awards and funding from the National Institutes of Health, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, American Society for Clinical Investigation, American Dermatological Association, and the International League ...